share_log

6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

SEC ·  Dec 20 19:10
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more